April 7 (Reuters) - Insmed (INSM.O), opens new tab said on Tuesday it ‌would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage ...

Confused between Python and R? Discover which language dominates data science in 2026. Compare AI power, visualization, and real-world use cases to pick the right career path. Whether beginner or pro, ...

A new study from Monash University reveals that adults with Attention-Deficit/Hyperactivity Disorder (ADHD) experience brief sleep-like brain activity during the day ...

A Grabpack Test is a puzzle experience where you use the titular tools to manipulate elements on the map and reach the end of the level. This title combines puzzle-style level design with platformer ...

A new study suggests a substance in python blood could lead to new weight loss therapies for humans. The mice given the substance lost 9% of their body weight over 28 days. Scientists believe this ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North Carolina biotech has presented promising results for the TYK2/JAK1 inhibitor in ...

Pfizer (PFE) announced on Tuesday that a mid-stage trial evaluating a monthly maintenance dosing regimen of its experimental obesity drug indicated that the GLP-1 receptor agonist PF’3944 (MET-097i) ...

DALLAS—As pay TV operators continue to struggle with cord cutting and streaming platforms seeks to retain fickle consumers who regularly cancel subscriptions, a new study from Parks Associates takes a ...

A long-running Swedish study has followed adults for nearly five decades, uncovering when physical decline truly begins. Fitness and strength start slipping around age 35, then worsen gradually with ...